Settlement: Oracle, Angeion Group, Lieff Cabraser Heimann & Bernstein, LLP, United States district court

Oracle Settles Patent Infringement Suit Against Angeion Group For $5 Million

Angeion Group, a medical device company, has agreed to pay Oracle $5 million to settle a patent infringement lawsuit. The settlement was filed in the United States District Court for the Northern District of California on January 25, 2023.

Background of the Case

In 2021, Oracle filed a lawsuit against Angeion Group, alleging that the company's vascular closure devices infringed on Oracle's patents. Oracle claimed that Angeion's devices used technology that was similar to its own, and that Angeion had not obtained a license to use the technology.

Angeion denied the allegations, and the two companies entered into a settlement agreement to avoid a lengthy and costly trial.

Terms of the Settlement

Under the terms of the settlement, Angeion will pay Oracle $5 million. Angeion will also be required to stop selling the vascular closure devices that were accused of infringing on Oracle's patents.

In addition, Angeion has agreed to enter into a licensing agreement with Oracle, which will allow Angeion to continue to sell its vascular closure devices.

Impact of the Settlement

The settlement is a significant victory for Oracle, as it shows that the company is willing to protect its intellectual property rights.

The settlement also sends a message to other companies that they should be careful not to infringe on Oracle's patents.

Statement from Oracle

"We are pleased with the outcome of this case," said Dorian Daley, Oracle's general counsel. "This settlement shows that Oracle is committed to protecting its intellectual property rights."

Statement from Angeion Group

"We are pleased to have reached a settlement with Oracle," said Matt Kaplan, Angeion Group's CEO. "This settlement allows us to continue to focus on our business and to provide our customers with high-quality medical devices."

Conclusion

The settlement between Oracle and Angeion Group is a significant development in the ongoing battle over intellectual property rights in the medical device industry. The settlement shows that Oracle is willing to protect its patents, and that it will not hesitate to take legal action against companies that infringe on its intellectual property rights.